[Cor bovinum: decreased incidence over the last 20 years--a therapeutic success?]

S Fluri1, J O Gebbers

  • 1Pathologisches Institut, Kantonsspital Luzern.

Praxis
|January 31, 2002
PubMed

Insights

Cor bovinum (CB), a significantly enlarged heart, is a common autopsy finding. Its frequency is decreasing, possibly due to advances in cardiovascular treatment, though it remains linked to sudden cardiac death.

Area of Science:

  • Cardiovascular Pathology
  • Forensic Medicine
  • Internal Medicine

Context:

  • Cor bovinum (CB), a heart weighing over 500g, is frequently observed in autopsies of patients with unclear causes of death.
  • Cardiomyocyte hypertrophy and interstitial fibrosis in CB can lead to electromechanical instability and sudden cardiac death.

Purpose:

  • To compare the frequency of Cor bovinum (CB) and associated pathologies in two distinct 4-year periods (1978-1981 and 1997-2000).
  • To analyze trends in CB prevalence, patient demographics, and risk factors over two decades.

Summary:

  • A retrospective autopsy study of 1181 patients revealed a decrease in CB prevalence from 25.3% (1978-1981) to 20.6% (1997-2000).
  • The mean age at death increased significantly, with hypertension, COPD, and male sex identified as primary risk factors for CB. In 84% of CB cases, death was directly related to the condition.
  • Despite a decreasing trend, CB remains a frequent finding, often associated with clinically unclear causes of death.

Impact:

  • The observed decrease in CB frequency and increase in age at death suggest improved cardiovascular care and therapeutic interventions.
  • Findings highlight the importance of managing hypertension and COPD to mitigate risks associated with Cor bovinum.
  • This study provides valuable insights into the evolving landscape of cardiovascular pathology and its clinical implications.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...